Skip to content
IJCBR|ISSN: 2521-0394
Log in
IJ
IJCBR
Original Research ArticlesPeer-reviewedOpen Access · CC BY 4.0

PROTECTIVE EFFECT OF DIOSGENIN AGAINST CARBON TETRACHLORIDE AND CISPLATIN INDUCED HEPATOTOXICITY IN RATS

Vikram V Nimbalkar1, Ravina P Shelke2, Urmila E Kadu3, Pandurang M Gaikwad4

  1. 1 Department of Pharmacology, Dr. Vithalrao Vikhe Patil Foundation’s College of Pharmacy, Vilad Ghat, Ahmednagar (MS), India
  2. 2 Department of Pharmacology, Dr. Vithalrao Vikhe Patil Foundation’s College of Pharmacy, Vilad Ghat, Ahmednagar (MS), India (corresponding author)
  3. 3 Department of Pharmacology, Dr. Vithalrao Vikhe Patil Foundation’s College of Pharmacy, Vilad Ghat, Ahmednagar (MS), India
  4. 4 Department of Pharmacology, Dr. Vithalrao Vikhe Patil Foundation’s College of Pharmacy, Vilad Ghat, Ahmednagar (MS), India

DOI: 10.31878/ijcbr.2018.43.11 · Published 2018-07-31 · pp. 50-56

Download PDF

Abstract

Background: Activation of hepatic stellate cells (HSC) plays central role in the development of liver fibrosis. In HSC activation, the transforming growth factor-1 (TGF-1) is considered to be the main stimuli factor. Diosgenin are the steroidal saponin and found in Trigonella foenum graecum Linn (Fenugreek) and some other species of Dioscorea. Diosgenin attenuates HSC activation by inhibiting transforming growth factor. Aim: In present study an attempt was made to explore the effect of diosgenin on liver fibrosis. Methods: Liver fibrosis was induced in rats by carbon tetrachloride (CCl4) 1 ml/kg intraperitoneally twice a week for 28 days and cisplatin 3mg/kg intraperitoneally at 0, 1, 3 week for 4 weeks. The extent of liver fibrosis was assessed by measuring the weight of liver and levels of total bilirubin (TBL), hydroxyproline (HP) and serum enzymes due to deposition of extracellular matrix (ECM). Results: The administration of diosgenin reduced the liver weight of CCl4 and cisplatin treated animals and reduced the TBL, HP level and serum enzymes significantly and inhibited liver fibrosis induced by CCl4 and cisplatin. Conclusion: The result obtained in the present investigation, Diosgenin treatment exerted significant hepatoprotective effect in animals by inhibiting ECM deposition and HSCs activation.

References

  1. Thaakur SR, Saraswathy GR, Maheswari E, Kumar NS, Hazarathiah T, Sowmya K, et al. Inhibition of CCl4- induced liver fibrosis by Trigonella foenum-graecum Linn. Natural Product Radiance. 2007;6 (1):11-17. [Crossref] [Google Scholar]
  2. Xie WL, Jiang R, Shen XL, Chen ZY, Deng XM. Diosgenin attenuates hepatic stellate cell activation through transforming growth factor-β/Smad signaling pathway. Int J Clin Exp Med. 2015;8(11):20323-20329. [Crossref] [Google Scholar]
  3. Elpek GO. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol. 2014;20(23):7260-7276. [Crossref] [Google Scholar]
  4. Henderson NC, Iredale JP. Liver fibrosis: cellular mechanisms of progression and resolution. Clinical Science. 2007:112:265–280. [Crossref] [Google Scholar]
  5. Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and hepatic cirrhosis: comparison with viral hepatitis-associated steatosis. World J Gastroenterol. 2015;21(46):12989-12995. [Crossref] [Google Scholar]
  6. Bert F. Liver Fibrosis: Difficulties in Diagnostic and Treatment: A Review. Gastro Med Res. 2017;1(1):1-8. [Crossref] [Google Scholar]
  7. Weiskirchen R, Tacke F. Liver Fibrosis: Which Mechanisms Matter? Clinical Liver Disease. 2016;8(4):94-99. [Crossref] [Google Scholar]
  8. Lingwal P, Bhatt GK, Kothiyal P. Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis. International Journal of Pharma Research & Review. 2015;4(7):32-37. [Crossref] [Google Scholar]
  9. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol. 2006;12(46):7413-7420. [Crossref] [Google Scholar]
  10. Chen SR, Chen XP, Lu JJ, Wang Y, Wang YT. Potent natural products and herbal medicines for treating liver fibrosis. Chinese Medicine.2015;10(7):1-13. [Crossref] [Google Scholar]
  11. Yuan Q, Wu X, Huang W, Gong G, et al. Acute toxicity and sub-chronic toxicity of steroidal saponins from Dioscorea zingiberensis C.H. Wright in rodents. Journal of Ethnopharmacology. 2009;126(3):543–550. [Crossref] [Google Scholar]
  12. Dong S, Chen QL, Song YN, Sun Y, Wei B, Li XY, et al. mechanism of CCl4-induced liver fibrosis with combined transcriptomic and proteomic analysis. Journal of Toxicological Sciences. 2016;41(4);561-572. [Crossref] [Google Scholar]
  13. Mir M, Arab MR, Shahraki MR. Toxic effects of cisplatin on hepatocytes and liver enzymes of rats. Anatomical Science. 2015;12(4):171-176. [Crossref] [Google Scholar]
  14. Katagiri D, Hamasaki Y, Doi K, Negishi K, et al. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. Kidney International. 2016;89:374-385. [Crossref] [Google Scholar]
  15. Rajesh MG, Latha MS. Protective activity of Glycyrrhiza glabra Linn. On carbon tetrachloride induced peroxidative damage. Indian J Pharmacol. 2004;36(5):284-287. [Crossref] [Google Scholar]
  16. Mustafa I, Elif O, Mukaddes G, Seda T. Protective effect of caffeic acid phenethyl ester (CAPE) administration on cisplatin-induced oxidative damage to liver in rat. Cell Biochem Funct. 2006;24:357–361. [Crossref] [Google Scholar]